# Macrogenics Inc: overview MGNX · Nasdaq · CIK 1125345 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/mgnx.md) · [Financials](/companies/mgnx/financials.md) · [Filings](/companies/mgnx/filings.md) · [Insiders](/companies/mgnx/insiders.md) Latest reported revenue: [$32.8m](/filings/0001125345-26-000056.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:Revenues, accession 0001125345-26-000056). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [111](/filings/0001125345-25-000108.md) | [19.4 d](/filings/0001125345-26-000017.md) | [13.2](/filings/0001125345-26-000038.md) | [6.9](/filings/0001125345-26-000056.md) | [72.8](/filings/0001125345-25-000108.md) | [41.2 d](/filings/0001125345-26-000017.md) | [20.8](/filings/0001125345-26-000038.md) | [32.8](/filings/0001125345-26-000056.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [48.9%](/filings/0001125345-25-000108.md) | [(273.0%) d](/filings/0001125345-26-000017.md) | [(323.1%)](/filings/0001125345-26-000038.md) | [(629.3%)](/filings/0001125345-26-000056.md) | [25.6%](/filings/0001125345-25-000108.md) | [(29.3%) d](/filings/0001125345-26-000017.md) | [(161.0%)](/filings/0001125345-26-000038.md) | [(42.2%)](/filings/0001125345-26-000056.md) | | Net margin | % | [50.9%](/filings/0001125345-25-000108.md) | [(79.7%) d](/filings/0001125345-26-000017.md) | [(311.1%)](/filings/0001125345-26-000056.md) | [(527.7%)](/filings/0001125345-26-000056.md) | [23.1%](/filings/0001125345-25-000108.md) | [(34.3%) d](/filings/0001125345-26-000017.md) | [(177.0%)](/filings/0001125345-26-000056.md) | [59.4%](/filings/0001125345-26-000056.md) | | Diluted EPS | $ per share | [0.90](/filings/0001125345-25-000108.md) | not reported | [(0.65)](/filings/0001125345-26-000038.md) | [(0.57)](/filings/0001125345-26-000056.md) | [0.27](/filings/0001125345-25-000108.md) | not reported | [(0.58)](/filings/0001125345-26-000038.md) | [0.31](/filings/0001125345-26-000056.md) | | Free cash flow | $m | [59.6 d](/filings/0001125345-25-000108.md) | [(39.0) d](/filings/0001125345-26-000017.md) | [(47.4)](/filings/0001125345-26-000038.md) | [(47.7) d](/filings/0001125345-26-000056.md) | [(30.6) d](/filings/0001125345-25-000108.md) | [42.8 d](/filings/0001125345-26-000017.md) | [(36.2)](/filings/0001125345-26-000038.md) | [(41.6) d](/filings/0001125345-26-000056.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [77.4](/filings/0001125345-24-000060.md) | [152](/filings/0001125345-25-000042.md) | [58.7](/filings/0001125345-26-000017.md) | [150](/filings/0001125345-26-000017.md) | [150](/filings/0001125345-26-000017.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(261.9%)](/filings/0001125345-24-000060.md) | [(79.9%)](/filings/0001125345-25-000042.md) | [(286.4%)](/filings/0001125345-26-000017.md) | [(73.7%)](/filings/0001125345-26-000017.md) | [(48.7%)](/filings/0001125345-26-000017.md) | | Net margin | % | [(261.0%)](/filings/0001125345-24-000060.md) | [(78.8%)](/filings/0001125345-25-000042.md) | [(15.4%)](/filings/0001125345-26-000017.md) | [(44.7%)](/filings/0001125345-26-000017.md) | [(49.9%)](/filings/0001125345-26-000017.md) | | Diluted EPS | $ per share | [(3.37)](/filings/0001125345-24-000060.md) | [(1.95)](/filings/0001125345-25-000042.md) | [(0.15)](/filings/0001125345-26-000017.md) | [(1.07)](/filings/0001125345-26-000017.md) | [(1.18)](/filings/0001125345-26-000017.md) | | Free cash flow | $m | [(150)](/filings/0001125345-24-000060.md) | [(90.6)](/filings/0001125345-25-000042.md) | [(80.0)](/filings/0001125345-26-000017.md) | [(72.1)](/filings/0001125345-26-000017.md) | [(83.0)](/filings/0001125345-26-000017.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/mgnx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [ARMISTICE CAPITAL, LLC](/funds/1601086.md) | 2026-06-30 | $23.1m | 5,006,752 | | Reduced −1,005,248 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $21.6m | 4,679,229 | | Added +3,516,083 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $12.3m | 2,656,010 | | Added +2,157 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $12.2m | 2,632,750 | | Reduced −330,809 | | [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $11.5m | 2,488,252 | | Added +86,438 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $11.4m | 2,465,699 | | Reduced −62,130 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $11.0m | 2,374,296 | | Reduced −420,061 | | [WASATCH ADVISORS LP](/funds/814133.md) | 2026-06-30 | $9.3m | 2,018,881 | | Added +459,180 | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $8.6m | 1,864,176 | | Unchanged | | [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $8.4m | 1,820,231 | | Added +611,456 | ## Recent filings [All 925 filings](/companies/mgnx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-23 | 20:05 ET | [8-K](/filings/0001125345-26-000066.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001125345-26-000066 | | 2026-09-03 | 20:39 ET | [8-K/A](/filings/0001125345-26-000059.md) | 9.01 Financial statements and exhibits | 0001125345-26-000059 | | 2026-08-14 | 20:19 ET | [10-Q](/filings/0001125345-26-000056.md) | Quarterly report, period 2026-06-30 | 0001125345-26-000056 | | 2026-08-13 | 20:07 ET | [8-K](/filings/0001125345-26-000054.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001125345-26-000054 | | 2026-07-23 | 20:07 ET | [8-K](/filings/0001125345-26-000050.md) | 8.01 Other events | 0001125345-26-000050 | | 2026-07-08 | 20:00 ET | [8-K](/filings/0001125345-26-000047.md) | 5.02 Departure or appointment of officers or directors | 0001125345-26-000047 | | 2026-07-07 | 20:30 ET | [8-K](/filings/0001125345-26-000045.md) | 2.01 Completion of an acquisition or disposition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001125345-26-000045 | | 2026-05-20 | 20:01 ET | [8-K](/filings/0001125345-26-000042.md) | 5.07 Shareholder vote results | 0001125345-26-000042 | | 2026-05-13 | 20:22 ET | [8-K](/filings/0001125345-26-000040.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001125345-26-000040 | | 2026-05-13 | 20:13 ET | [10-Q](/filings/0001125345-26-000038.md) | Quarterly report, period 2026-03-31 | 0001125345-26-000038 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001125345-26-000017.md), filed Mar 9, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/0fec61e3-9c39-4b04-af44-5e86d8baa72a) ## About the filer - CIK: 1125345 - Tickers: MGNX - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.